Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Early Breast Cancer Trailists’ Collaborative Group EBCTCG

Research output: Contribution to journalArticleAcademicpeer-review

703 Citations (Web of Science)

Abstract

Background the optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.
Original languageEnglish
Pages (from-to)1341-1352
JournalLancet
Volume386
Issue number10001
DOIs
Publication statusPublished - 3 Oct 2015

Cite this